Global NASH Non alcoholic Steatohepatitis Biomarkers Market Size By Type (Serum Biomarkers, Hepatic Fibrosis Biomarkers), By Application (Pharma And CRO Industry, Hospitals), By Region, And Segment Fo...

lobal NASH (Non-Alcoholic Steatohepatitis) Biomarkers Market Report Description

The Global NASH Biomarkers Market was valued at USD 1.2 billion in 2023 and is projected to reach USD 4.1 billion by 2031, growing at a CAGR of 16.7% during the forecast period from 2023 to 2031. The market is driven by the rising global prevalence of non-alcoholic fatty liver disease (NAFLD) and its progression to NASH, a condition marked by liver inflammation and damage. As the need for early and non-invasive diagnostic tools escalates, biomarker-based solutions are gaining significant traction for their accuracy, convenience, and predictive capabilities.

Drivers:

1. Rising Prevalence of NAFLD and NASH:

The global increase in obesity, diabetes, and metabolic syndromes is fueling the incidence of NAFLD and its progression to NASH. This rising burden is pushing demand for early detection tools, where biomarkers are proving essential.

2. Shift Toward Non-Invasive Diagnostic Tools:

Liver biopsy, the current gold standard, is invasive and risky. Biomarkers offer a non-invasive, repeatable, and cost-effective alternative, encouraging healthcare systems to adopt them as part of diagnostic protocols.

3. Expanding Pipeline of NASH Therapeutics:

Pharmaceutical companies are actively developing NASH treatments, and biomarkers are pivotal for patient stratification, drug efficacy evaluation, and trial success—further stimulating the biomarker market.

Restraints:

1. Lack of Standardization:

There is currently no universal agreement on the most effective and accurate NASH biomarkers, which hampers regulatory approvals and widespread clinical adoption.

2. Limited Awareness and Screening:

Despite the high disease burden, many patients remain undiagnosed due to limited awareness and poor access to diagnostic screening, especially in low-resource settings.

Opportunity:

1. Emerging Biomarker Technologies:

Advancements in omics technologies (genomics, proteomics, metabolomics) are opening avenues for novel biomarker discovery, enabling more precise diagnosis and monitoring.

2. Growing Adoption in Clinical Trials:

The pharmaceutical industry's rising reliance on companion diagnostics and biomarkers for NASH drug development offers lucrative opportunities for biomarker developers.

Market by System Type Insights:

The serum biomarkers segment led the market in 2023 due to ease of sampling, established clinical use, and robust correlation with disease severity. However, genomic biomarkers are expected to witness the fastest growth owing to increasing interest in personalized medicine and risk stratification in preclinical NASH.

Market by End-use Insights:

Pharmaceutical and biotechnology companies dominated the end-use segment, driven by growing R&D in NASH therapeutics. These companies rely on biomarkers for patient recruitment, stratification, and drug response monitoring in clinical trials. The diagnostic laboratories segment is anticipated to grow steadily as biomarker-based tests gain regulatory approval and clinical trust.

Market by Regional Insights:

North America held the largest market share in 2023, owing to a high prevalence of metabolic disorders, robust healthcare infrastructure, and ongoing clinical trials. Meanwhile, Asia-Pacific is expected to grow at the highest rate during the forecast period, propelled by increasing lifestyle-related diseases, healthcare reforms, and emerging diagnostic companies.

Competitive Scenario:

Key players in the Global NASH Biomarkers Market include GENFIT SA, Siemens Healthineers, Echosens, LabCorp, Quest Diagnostics, BioPredictive, Owlstone Medical, Perspectum Diagnostics, Thermo Fisher Scientific, and Roche Diagnostics. These companies are focusing on partnerships, biomarker discovery, and commercialization strategies. Noteworthy developments include:

In 2024, GENFIT SA announced the launch of its NIS4+ biomarker panel for broader diagnostic use.

Perspectum Diagnostics received regulatory approval for its LiverMultiScan platform in new Asian markets in 2023.

Echosens collaborated with pharmaceutical firms in 2022 to integrate biomarker testing into clinical NASH trials.

Scope of Work – Global NASH Biomarkers Market

Report Metric Details

Market Size (2023) USD 1.2 billion

Projected Market Size (2031) USD 4.1 billion

CAGR (2023-2031) 16.7%

Market Segments By System Type (Serum, Imaging, Genomic), By End-use

Growth Drivers Rising NAFLD/NASH prevalence, non-invasive diagnosis demand, expanding therapeutic pipeline

Opportunities Genomic biomarker innovation, clinical trial integration

Key Market Developments:

2023: BioPredictive introduced a machine-learning-powered NASH biomarker platform integrating fibrosis scores with multi-omics data.

2024: Siemens Healthineers expanded its biomarker test offerings for liver disease diagnostics into Latin America.

2025: Quest Diagnostics and Roche announced a strategic partnership to co-develop blood-based NASH diagnostic panels.

FAQs:

What is the current market size of the Global NASH Biomarkers Market?

The market was valued at USD 1.2 billion in 2023.

What is the major growth driver of the Global NASH Biomarkers Market?

The key driver is the increasing need for non-invasive diagnostic solutions amid rising NASH prevalence.

Which is the largest region during the forecast period in the Global NASH Biomarkers Market?

North America is expected to remain the largest regional market.

Which segment accounted for the largest market share in Global NASH Biomarkers Market?

The Serum Biomarkers segment accounted for the largest market share in 2023.

Who are the key market players in the Global NASH Biomarkers Market?

Key players include GENFIT SA, Siemens Healthineers, Echosens, LabCorp, Quest Diagnostics, and Perspectum Diagnostics.

Would you like a visual chart or infographic to accompany this report?